Company overview
Nona Biosciences provides integrated antibody discovery, engineering, and development services using proprietary fully human transgenic mice platforms like Harbour Mice and HCAbs. Capabilities include bispecific/multispecific engineering, mRNA-LNP delivery, phage/yeast display, and AI-enhanced platforms such as Hu-mAtrIx for optimized lead selection. The company supports projects from antigen preparation through IND-enabling studies and early clinical development.
Nona Biosciences is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include antibody discovery, fully human antibodies, bispecific engineering, hcab platform, mrna-lnp therapeutics.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://nonabio.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- antibody discovery, fully human antibodies, bispecific engineering, hcab platform, mrna-lnp therapeutics
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What antibody discovery platforms does Nona Biosciences offer?
- Nona offers fully human antibody discovery using HCAb Harbour Mice for single-domain VH antibodies, phage display, yeast display, and AI-powered Hu-mAtrIx for binding prediction and developability assessment.
- What engineering capabilities are available for bispecific antibodies?
- Nona provides bispecific and multispecific engineering with HCAb platforms, modular screening of constructs, antigen preparation, and developability assessments to de-risk development.
- Does Nona support clinical development stages?
- Yes, Nona has expanded to integrated discovery-to-clinical capabilities, including CMC development, toxicology, IND-enabling activities, and support for early clinical development and Investigator-Initiated Trials.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
